Peer-influenced content. Sources you trust. No registration required. This is HCN.

HealioSURMOUNT-1: Adults Achieve Weight Loss of 16% or More at 72 Weeks with Tirzepatide

Clinical trials of a new weight loss medication have found that adults with obesity taking the once-weekly GIP/GLP-1 receptor agonist tirzepatide achieved a mean weight loss of at least 16% at 72 weeks. Most side effects observed were mild to moderate, with the most common being nausea, diarrhea, constipation, and vomiting. The results are considered encouraging.